Table 2 Changes in cMRI measured RV parameters following treatment for 6 months with either empagliflozin or placebo
Empagliflozin 10 mg (n = 44)* | Placebo (n = 46)* | ||||||
|---|---|---|---|---|---|---|---|
Baseline | 6 months | Mean change (95% CI) | Baseline | 6 months | Mean change (95% CI) | ||
RV mass index, g/m2 | 11.5 (2.35) | 11.4 (2.13) | − 0.07 (− 0.64 to 0.50) | 12.8 (2.37) | 11.8 (1.84) | − 0.28 (− 0.96 to 0.40) | |
RV end diastolic volume index, mL/m2 | 62.0 (13.2) | 61.7 (10.8) | − 0.53 (− 3.22 to 2.16) | 66.4 (12.6) | 65.5 (10.4) | − 0.84 (− 3.15 to 1.47) | |
RV end systolic volume index, mL/m2 | 28.9 (6.51) | 28.6 (6.24) | − 0.48 (− 1.99 to 1.03) | 30.8 (6.98) | 30.4 (5.60) | − 0.27 (− 1.63 to 1.08) | |
RV ejection fraction, % | 53.2 (4.93) | 53.7 (5.17) | 0.53 (− 1.02 to 2.08) | 53.8 (4.59) | 53.5 (5.13) | − 0.35 (− 1.82 to 1.12) | |